41 research outputs found
Virus infection elevates transcriptional activity of miR164a promoter in plants
Background: Micro RNAs (miRs) constitute a large group of endogenous small RNAs that have crucial roles in many important plant functions. Virus infection and transgenic expression of viral proteins alter accumulation and activity of miRs and so far, most of the published evidence involves post-transcriptional regulations.
Results: Using transgenic plants expressing a reporter gene under the promoter region of a characterized miR (P-miR164a), we monitored the reporter gene expression in different tissues and during Arabidopsis development. Strong expression was detected in both vascular tissues and hydathodes. P-miR164a activity was developmentally regulated in plants with a maximum expression at stages 1.12 to 5.1 (according to Boyes, 2001) along the transition from vegetative to reproductive growth. Upon quantification of P-miR164a-derived GUS activity after Tobacco mosaic virus Cg or Oilseed rape mosaic virus (ORMV) infection and after hormone treatments, we demonstrated that ORMV and gibberellic acid elevated P-miR164a activity. Accordingly, total mature miR164, precursor of miR164a and CUC1 mRNA (a miR164 target) levels increased after virus infection and interestingly the most severe virus (ORMV) produced the strongest promoter induction.
Conclusion: This work shows for the first time that the alteration of miR pathways produced by viral infections possesses a transcriptional component. In addition, the degree of miR alteration correlates with virus severity since a more severe virus produces a stronger P-miR164a induction.Instituto de BiotecnologĂaFil: Bazzini, Ariel Alejandro. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Almasia, Natalia Ines. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Manacorda, Carlos Augusto. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; ArgentinaFil: Mongelli, Vanesa Claudia. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Conti, Gabriela. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; ArgentinaFil: Maroniche, Guillermo AndrĂ©s. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Rodriguez, Maria Cecilia. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Distefano, Ana Julia. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Hopp, Horacio Esteban. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Del Vas, Mariana. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Asurmendi, Sebastian. Instituto Nacional de TecnologĂa Agropecuaria (INTA). Instituto de BiotecnologĂa; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentin
Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence
Introduction and objectives: The incidence of cholangiocarcinoma (CCA) has been increasing globally. Although a concomitant increase in the incidence of metabolic disorders might suggest a causal relationship, the data are scarce. We aimed to describe the prevalence of metabolic disorders in patients with CCA and report the clinical features and outcomes. Patients and Methods: Retrospective study including patients with CCA. Patients were divided into: (1) past history of diabetes or/and overweight/obesity (âmetabolic disorder groupâ) and (2) without any of these features (ânon-metabolic-disorder groupâ). A Cox regression model was used to determine the prognostic factors. Results: 122 patients were included. In total, 36 (29.5%) had overweight/obesity, 24 (19.7%) had diabetes, and 8 (6.6%) had both. A total of 29 (23.8%) patients had resectable disease and received upfront surgery. A total of 104 (85.2%) received chemotherapy for advanced/recurrent disease. The overall survival of the cohort was 14.3 months (95% CI: 10.1â17.3). ECOG-PS 0 (p < 0.0001), resectable disease (p = 0.018) and absence of vascular invasion (p = 0.048) were independently associated with better prognosis. The âmetabolic disorder groupâ (n = 52) had a median survival of 15.5 months (95% CI 10.9â33.9) vs. 11.5 months (95% CI 8.4â16.5) in the ânon-metabolic-disorder groupâ (n = 70) (HR: 1.10; 95% CI 0.62â1.94). Patients with resectable disease in the âmetabolic groupâ had longer survival than patients in the ânon-metabolic groupâ (43.4 months (95% CI 33.9-NR) vs. 21.8 months (95% CI 8.6â26.9); HR = 0.12, 95% CI 0.03â0.59). Conclusion: Metabolic disorders are frequent among CCA patients. Underlying metabolic comorbidities may be associated with prognosis in resectable CCA. There is a need to explore the mechanism that drives CCA carcinogenesis in a metabolic background
Estimating unknown values in reciprocal intuitionistic preference relations via asymmetric fuzzy preference relations
Intuitionistic preference relations are becoming increasingly important in the field of group decision making since they present a flexible and simple way to the experts to provide their preference relations, while at the same time allowing them to accommodate a certain degree of hesitation inherent to all decision making processes. In this contribution, we prove the mathematical equivalence between the set of asymmetric fuzzy preference relations and the set of reciprocal intuitionistic fuzzy preference relations. This result is exploited to tackle the presence of incomplete reciprocal intuitionistic fuzzy preference relation in decision making by developing a consistency driven estimation procedure via the corresponding equivalent incomplete asymmetric fuzzy preference relation
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
[EN]Objective Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. We aimed to clarify the impact of RIPK3 signalling in the pathogenesis of human and experimental NAFLD.
Design RIPK3 levels were evaluated in two large independent cohorts of patients with biopsy proven NAFLD diagnosis and correlated with clinical and biochemical parameters. Wild-type (WT) or Ripk3-deficient (Ripk3(-/-)) mice were fed a choline-deficient L-amino acid-defined diet (CDAA) or an isocaloric control diet for 32 and 66 weeks.
Results RIPK3 increased in patients with non-alcoholic steatohepatitis (NASH) in both cohorts, correlating with hepatic inflammation and fibrosis. Accordingly, Ripk3 deficiency ameliorated CDAA-induced inflammation and fibrosis in mice at both 32 and 66 weeks. WT mice on the CDAA diet for 66 weeks developed preneoplastic nodules and displayed increased hepatocellular proliferation, which were reduced in Ripk3(-/-) mice. Furthermore, Ripk3 deficiency hampered tumourigenesis. Intriguingly, Ripk3(-/-) mice displayed increased body weight gain, while lipidomics showed that deletion of Ripk3 shifted hepatic lipid profiles. Peroxisome proliferator-activated receptor. (PPAR.) was increased in Ripk3(-/-) mice and negatively correlated with hepatic RIPK3 in patients with NAFLD. Mechanistic studies established a functional link between RIPK3 and PPAR. in controlling fat deposition and fibrosis.
Conclusion Hepatic RIPK3 correlates with NAFLD severity in humans and mice, playing a key role in managing liver metabolism, damage, inflammation, fibrosis and carcinogenesis. Targeting RIPK3 and its intricate signalling arises as a novel promising approach to treat NASH and arrest disease progression.Main funding is provided by FEDER funds through the COMPETE programme and by national funds through Fundacao para a Ciencia e a Tecnologia to CMPR (grants SAICTPAC/0019/2015-LISBOA-01-0145--FEDER-016405 and PTDC/MED-FAR/29097/2017 -LISBOA-01-0145-FEDER-029097). Additional funding comes from research grant APEF (Portuguese Association for the Study of Liver)/BAYER 2020 to MBA. JG is funded by the Fondation pour la Recherche Medicale (ARF20170938613), the Institute of Cardiometabolism and Nutrition (PAP17NECJG), the Societe Francophone du Diabete (R19114DD) and the Mairie de Paris (Emergences -R18139DD). MBA, PMR, MMP and ALS were investigators or students funded by Fundacao para a Ciencia e a Tecnologia
Metabolic and miRNA Profiling of TMV Infected Plants Reveals Biphasic Temporal Changes
Plant viral infections induce changes including gene expression and metabolic components. Identification of metabolites and microRNAs (miRNAs) differing in abundance along infection may provide a broad view of the pathways involved in signaling and defense that orchestrate and execute the response in plant-pathogen interactions. We used a systemic approach by applying both liquid and gas chromatography coupled to mass spectrometry to determine the relative level of metabolites across the viral infection, together with a miRs profiling using a micro-array based procedure. Systemic changes in metabolites were characterized by a biphasic response after infection. The first phase, detected at one dpi, evidenced the action of a systemic signal since no virus was detected systemically. Several of the metabolites increased at this stage were hormone-related. miRs profiling after infection also revealed a biphasic alteration, showing miRs alteration at 5 dpi where no virus was detected systemically and a late phase correlating with virus accumulation. Correlation analyses revealed a massive increase in the density of correlation networks after infection indicating a complex reprogramming of the regulatory pathways, either in response to the plant defense mechanism or to the virus infection itself. Our data propose the involvement of a systemic signaling on early miRs alteration
Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease
Background and Aims Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of symptomatic biliary cysts. Current surgical and pharmacological approaches are ineffective, and liver transplantation represents the only curative option. Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits. Approach and Results Here, we tested an approach based on the design, synthesis, and validation of a family of UDCA synthetic conjugates with selective HDAC6i capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conjugates presented selective HDAC6i activity, UDCA-HDAC6i #1 being the most promising candidate. UDCA orientation within the UDCA-HDAC6i structure was determinant for HDAC6i activity and selectivity. Treatment of polycystic rats with UDCA-HDAC6i #1 reduced their hepatomegaly and cystogenesis, increased UDCA concentration, and inhibited HDAC6 activity in liver. In cystic cholangiocytes UDCA-HDAC6i #1 restored primary cilium length and exhibited potent antiproliferative activity. UDCA-HDAC6i #1 was actively transported into cells through BA and organic cation transporters. Conclusions These UDCA-HDAC6i conjugates open a therapeutic avenue for PLDs.Supported by the Spanish Carlos III Health Institute (ISCIII; J.M. Banales: FIS PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129; M.J. Perugorria: PI14/00399, PI17/00022; J.J.G. Marin: FIS PI16/00598) cofinanced by "Fondo Europeo de Desarrollo Regional" (FEDER); CIBERehd (ISCIII): J.M. Banales, M.J. Perugorria, L. Bujanda, and J.J.G. Marin; Spanish Ministry of Economy and Competitiveness (M. J. Perugorria: Ramon y Cajal Program RYC-2015-17755); IKERBASQUE, Basque foundation for Science (M.J. Perugorria and J.M. Banales), Spain; "Junta de Castilla y Leon" (J.J.G. Marin: SA06P17); " Diputacion Foral Gipuzkoa" (J.M. Banales: DFG15/010, DFG16/004; M.J. Perugorria: DFG18/114, DFG19/081), BIOEF (Basque Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/BD to J.M. Banales), Department of Health of the Basque Country (J.M. Banales: 2017111010; M.J. Perugorria: 2019111024), and Euskadi RIS3 (J.M. Banales: 2016222001, 2017222014, and 2018222029; 2019222054); La Caixa Scientific Foundation (J.M. Banales: HR17-00601); "Fundacion Cientifica de la Asociacion Espanola Contra el Cancer" (AECC Scientific Foundation, to J.M. Banales and J.J.G. Marin); and "Centro Internacional sobre el Envejecimiento", Spain (J.J.G. Marin: OLD-HEPAMARKER, 0348-CIE-6-E). F.J. Caballero-Camino was funded by the Spanish Ministry of Science and Innovation (BES-2014-069148), A. Santos-Laso by the Basque Government (PRE_2018_2_0195), and Pui Y. Lee-Law by the European Association for the Study of the Liver (EASL; Sheila Sherlock Award). The Spanish Ministry of Science and Innovation supported F. P. Cossio: (CTQ2016-80375-P and CTQ2014-51912-REDC) as well as the Basque Government (F.P. Cossio: IT-324-07). I. Rivilla had a postdoctoral contract from the Donostia International Physics Center
Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD
[EN] Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease where liver biopsy remains the gold standard for diagnosis. Here we aimed
to evaluate the role of circulating adiponectin, leptin, and insulin-like growth factor
1 (IGF-1) levels as non-invasive NAFLD biomarkers and assess their correlation with
the metabolome.
Materials and Methods: Leptin, adiponectin, and IGF-1 serum levels were measured
by ELISA in two independent cohorts of biopsy-proven obese NAFLD patients and
healthy-liver controls (discovery: 38 NAFLD, 13 controls; validation: 194 NAFLD,
31 controls) and correlated with clinical data, histology, genetic parameters, and
serum metabolomics.
Results: In both cohorts, leptin increased in NAFLD vs. controls (discovery: AUROC
0.88; validation: AUROC 0.83; p < 0.0001). The leptin levels were similar between
obese and non-obese healthy controls, suggesting that obesity is not a confounding
factor. In the discovery cohort, adiponectin was lower in non-alcoholic steatohepatitis
(NASH) vs. non-alcoholic fatty liver (AUROC 0.87; p < 0.0001). For the validation
cohort, significance was attained for homozygous for PNPLA3 allele c.444C (AUROC
0.63; p < 0.05). Combining adiponectin with specific serum lipids improved the assay
performance (AUROC 0.80; p < 0.0001). For the validation cohort, IGF-1 was lower with advanced fibrosis (AUROC 0.67, p<0.05), but combination with international normalized
ratio (INR) and ferritin increased the assay performance (AUROC 0.81; p < 0.01).
Conclusion: Serum leptin discriminates NAFLD, and adiponectin combined with
specific lipids stratifies NASH. IGF-1, INR, and ferritin distinguish advanced fibrosis.CR was funded by FEDER through the COMPETE program
and by national funds through Fundação para a CiĂȘncia
e a Tecnologia (PTDC/MED-FAR/29097/2017âLISBOA-01-
0145-FEDER-029097) and by European Horizon 2020 (H2020-
MSCA-RISE-2016-734719). This work was also supported by
Fundação para a CiĂȘncia e Tecnologia (PD/BD/135467/2017)
and Portuguese Association for the Study of Liver/MSD
2017. JB was funded by Spanish Carlos III Health Institute
(ISCIII) (PI15/01132, PI18/01075 and Miguel Servet Program
CON14/00129 and CPII19/00008), co-financed by Fondo
Europeo de Desarrollo Regional (FEDER), Instituto de Salud
Carlos III (CIBERehd, Spain), La Caixa Scientific Foundation
(HR17-00601), FundaciĂłn CientĂfica de la AsociaciĂłn Española
Contra el CĂĄncer, and European Horizon 2020 (ESCALON
project: H2020-SC1-BHC-2018-2020)
Metabolomic-Based Noninvasive Serum Test to Diagnose Nonalcoholic Steatohepatitis: Results From Discovery and Validation Cohorts
Nonalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease worldwide and includes a broad spectrum of histologic phenotypes, ranging from simple hepatic steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). While liver biopsy is the reference gold standard for NAFLD diagnosis and staging, it has limitations due to its sampling variability, invasive nature, and high cost. Thus, there is a need for noninvasive biomarkers that are robust, reliable, and cost effective. In this study, we measured 540 lipids and amino acids in serum samples from biopsy-proven subjects with normal liver (NL), NAFL, and NASH. Using logistic regression analysis, we identified two panels of triglycerides that could first discriminate between NAFLD and NL and second between NASH and NAFL. These noninvasive tests were compared to blinded histology as a reference standard. We performed these tests in an original cohort of 467 patients with NAFLD (90 NL, 246 NAFL, and 131 NASH) that was subsequently validated in a separate cohort of 192 patients (7 NL, 109 NAFL, 76 NASH). The diagnostic performances of the validated tests showed an area under the receiver operating characteristic curve, sensitivity, and specificity of 0.88 +/- 0.05, 0.94, and 0.57, respectively, for the discrimination between NAFLD and NL and 0.79 +/- 0.04, 0.70, and 0.81, respectively, for the discrimination between NASH and NAFL. When the analysis was performed excluding patients with glucose levels >136 mg/dL, the area under the receiver operating characteristic curve for the discrimination between NASH and NAFL increased to 0.81 +/- 0.04 with sensitivity and specificity of 0.73 and 0.80, respectively. Conclusion: The assessed noninvasive lipidomic serum tests distinguish between NAFLD and NL and between NASH and NAFL with high accuracy.Supported by the National Institutes of Health Blueprint for Neuroscience Research (R01AT001576 to S.C.L., J.M.M.), Agencia Estatal de Investigacion of the Ministerio de Economia, Industria y Competitividad (SAF2014-52097R to J.M.M.), CIBER Hepatic and Digestive Diseases and Instituto de Salud Carlos III (PIE14/0003 to J.M.M.), Etorgai 2015-Gobierno Vasco (ER-2015/00015 to R.M., I.M.A., C.A., A.C.), Plan de Promocion de la Innovacion 2015-Diputacion Foral de Bizkaia (6/12/IN/2015/00131 to A.C., C.A.), National Institute of Diabetes and Digestive and Kidney Diseases (RO1DK81410 to A.J.S.), and Czech Ministry of Health (RVO VFN64165 to L.V.)
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
[EN] Objective Hepatocellular carcinoma (HCC) is a prevalent
and aggressive cancer usually arising on a background
of chronic liver injury involving inflammatory and hepatic
regenerative processes. The triggering receptor expressed
on myeloid cells 2 (TREM-2) is predominantly expressed in
hepatic non-parenchymal
cells and inhibits Toll-like
receptor
signalling, protecting the liver from various hepatotoxic
injuries, yet its role in liver cancer is poorly defined. Here,
we investigated the impact of TREM-2 on liver regeneration
and hepatocarcinogenesis.
Design TREM-2 expression was analysed in liver tissues
of two independent cohorts of patients with HCC and
compared with control liver samples. Experimental HCC
and liver regeneration models in wild type and Trem-2-/-
mice, and in vitro studies with hepatic stellate cells (HSCs)
and HCC spheroids were conducted.
Results TREM-2 expression was upregulated in human
HCC tissue, in mouse models of liver regeneration and
HCC. Trem-2-/- mice developed more liver tumours
irrespective of size after diethylnitrosamine (DEN)
administration, displayed exacerbated liver damage,
inflammation, oxidative stress and hepatocyte proliferation.
Administering an antioxidant diet blocked DEN-induced
hepatocarcinogenesis in both genotypes. Similarly,
Trem-2-/- animals developed more and larger tumours in
fibrosis-associated
HCC models. Trem-2-/- livers showed
increased hepatocyte proliferation and inflammation after
partial hepatectomy. Conditioned media from human HSCs
overexpressing TREM-2 inhibited human HCC spheroid
growth in vitro through attenuated Wnt ligand secretion.
Conclusion TREM-2 plays a protective role in
hepatocarcinogenesis via different pleiotropic effects,
suggesting that TREM-2 agonism should be investigated
as it might beneficially impact HCC pathogenesis in a
multifactorial manner.Spanish Ministry of Economy and Competitiveness and âInstituto de Salud
Carlos IIIâ grants (MJP (PI14/00399, PI17/00022 and Ramon y Cajal Programme
RYC-2015â17755); JMB (PI12/00380, PI15/01132, PI18/01075, Miguel Servet
Programme CON14/00129 and CPII19/00008) cofinanced by âFondo Europeo de
Desarrollo Regionalâ (FEDER); CIBERehd: MJP, JMB and LB), Spain; IKERBASQUE,
Basque foundation for Science (MJP and JMB), Spain; âDiputaciĂłn Foral de Gipuzkoaâ
(MJP: DFG18/114, DFG19/081; JMB: DFG15/010, DFG16/004); BIOEF (Basque
Foundation for Innovation and Health Research: EiTB Maratoia BIO15/CA/016/
BD to JMB); Department of Health of the Basque Country (MJP: 2015111100 and
2019111024; JMB: 2017111010), Euskadi RIS3 (JMB: 2016222001, 2017222014,
2018222029, 2019222054, 2020333010) Department of Industry of the Basque
Country (JMB: Elkartek: KK-2020/00008) and AECC Scientific Foundation (JMB).
AE-B
was funded by the University of the Basque Country (UPV/EHU) (PIF2014/11)
and by the short-term
training fellowship Andrew K Burroughs (European
Association for the Study of the Liver, EASL). IL and AA-L
were funded by the
Department of Education, Language Policy and Culture of the Basque Government
(PRE_2016_1_0152 and PRE_2018_1_0184). OS and SK were funded by the
Austrian Science Fund (FWF25801-B22,
FWF-P35168
to OS and L-Mac:
F 6104-B21
to SK). FO and DAM were funded by a UK Medical Research Council programme
Grant MR/R023026/1. DAM was also funded by the CRUK programme grant
C18342/A23390, CRUK/AECC/AIRC Accelerator Award A26813 and the MRC MICA
programme grant MR/R023026/1. JBA is supported by the Danish Medical Research
Council, Danish Cancer Society, Nordisk Foundation, and APM Foundation. CJOâR
and PM-G
are supported by Marie Sklodowska-Curie
Programme and EASL Sheila
Sherlock postdoctoral fellowships
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
[EN] BACKGROUND & AIMS: Cholangiocarcinoma (CCA) comprises a heterogeneous group of malignant tumors associated with dismal prognosis. Alterations in post-translational modifications (PTMs), including NEDDylation, result in abnormal protein dynamics, cell disturbances and disease. Herein, we investigate the role of NEDDylation in CCA development and progression.
METHODS: Levels and functions of NEDDylation, together with response to pevonedistat (NEDDylation inhibitor) or CRISPR/Cas9 against NAE1 were evaluated invitro, invivo and/or in patients with CCA. The development of preneoplastic lesions in Nae1+/- mice was investigated using an oncogene-driven CCA model. The impact of NEDDylation in CCA cells on tumor-stroma crosstalk was assessed using CCA-derived cancer-associated fibroblasts (CAFs). Proteomic analyses were carried out by mass-spectrometry.
RESULTS: The NEDDylation machinery was found overexpressed and overactivated in human CCA cells and tumors. Most NEDDylated proteins found upregulated in CCA cells, after NEDD8-immunoprecipitation and further proteomics, participate in the cell cycle, proliferation or survival. Genetic (CRISPR/Cas9-NAE1) and pharmacological (pevonedistat) inhibition of NEDDylation reduced CCA cell proliferation and impeded colony formation invitro. NEDDylation depletion (pevonedistat or Nae1+/- mice) halted tumorigenesis in subcutaneous, orthotopic, and oncogene-driven models of CCA invivo. Moreover, pevonedistat potentiated chemotherapy-induced cell death in CCA cells invitro. Mechanistically, impaired NEDDylation triggered the accumulation of both cullin RING ligase and NEDD8 substrates, inducing DNA damage and cell cycle arrest. Furthermore, impaired NEDDylation in CCA cells reduced the secretion of proteins involved in fibroblast activation, angiogenesis, and oncogenic pathways, ultimately hampering CAF proliferation and migration.
CONCLUSION: Aberrant protein NEDDylation contributes to cholangiocarcinogenesis by promoting cell survival and proliferation. Moreover, NEDDylation impacts the CCA-stroma crosstalk. Inhibition of NEDDylation with pevonedistat may represent a potential therapeutic strategy for patients with CCA.
LAY SUMMARY: Little is known about the role of post-translational modifications of proteins in cholangiocarcinoma development and progression. Herein, we show that protein NEDDylation is upregulated and hyperactivated in cholangiocarcinoma, promoting tumor growth. Pharmacological inhibition of NEDDylation halts cholangiocarcinogenesis and could be an effective therapeutic strategy to tackle these tumors.This article is based upon work from the COST Action CA18122 European Cholangiocarcinoma Network supported by COST (European Cooperation in Science and Technology: www.cost.eu)